Welcome to our dedicated page for Nabriva Therapeutics plc news (Ticker: NBRV), a resource for investors and traders seeking the latest updates and insights on Nabriva Therapeutics plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nabriva Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nabriva Therapeutics plc's position in the market.
Nabriva Therapeutics plc (NASDAQ: NBRV) reported a net loss of $23.3 million for Q1 2020, compared to $20.2 million in Q1 2019. Revenue decreased by $0.9 million to $0.8 million, primarily due to reduced collaboration revenues. The company's cash runway has been extended into Q4 2020, aided by prudent expense management. Managed care coverage for XENLETA is robust, covering nearly 70% of U.S. lives. However, future sales remain uncertain due to the COVID-19 pandemic. Nabriva aims for European approval of XENLETA and is restructuring its sales force.
Nabriva Therapeutics (NASDAQ: NBRV) announced a post-hoc analysis published in Open Forum Infectious Diseases, demonstrating that lefamulin achieves comparable time to clinical response and discharge readiness as moxifloxacin in hospitalized patients with community-acquired bacterial pneumonia (CABP). The study analyzed 926 patients, showing a median response time of 4 days for both treatments. Lefamulin's potential to enable early discharges could enhance cost-effectiveness in treating CABP, addressing significant safety concerns associated with fluoroquinolones.